share_log

Indaptus Therapeutics Analyst Ratings

Indaptus Therapeutics Analyst Ratings

Indaptus Therapeutics 分析
Benzinga ·  2023/08/08 06:19
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
08/08/2023 548.65% HC Wainwright & Co. → $12 Reiterates Buy → Buy
05/04/2023 548.65% HC Wainwright & Co. → $12 Reiterates → Buy
03/20/2023 548.65% HC Wainwright & Co. $15 → $12 Maintains Buy
03/08/2023 710.81% HC Wainwright & Co. → $15 Reiterates → Overweight
02/08/2023 710.81% HC Wainwright & Co. → $15 Reiterates → Buy
01/31/2022 710.81% HC Wainwright & Co. → $15 Assumes → Buy
10/19/2021 764.86% Maxim Group → $16 Upgrades Hold → Buy
日期 上行/下行 分析公司 目标价格变化 评级变化 上一次/当前评级
2023/08/08 548.65% HC Wainwright公司 →$12 重申 购买→购买
05/04/2023 548.65% HC Wainwright公司 →$12 重申 →购买
03/20/2023 548.65% HC Wainwright公司 $15→$12 维护
03/08/2023 710.81% HC Wainwright公司 →$15 重申 →超重
02/08/2023 710.81% HC Wainwright公司 →$15 重申 →购买
2022年1月31日 710.81% HC Wainwright公司 →$15 假设 →购买
10/19/2021 764.86% Maxim集团 →$16 升级 持有→购买

What is the target price for Indaptus Therapeutics (INDP)?

Indaptus Treeutics(INDP)的目标价格是多少?

The latest price target for Indaptus Therapeutics (NASDAQ: INDP) was reported by HC Wainwright & Co. on August 8, 2023. The analyst firm set a price target for $12.00 expecting INDP to rise to within 12 months (a possible 548.65% upside). 5 analyst firms have reported ratings in the last year.

HC Wainwright&Co.于2023年8月8日报道了Indaptus治疗公司(纳斯达克代码:INDP)的最新目标价。这家分析公司将目标价定为12美元,预计Indp将在12个月内升至(可能上涨548.65%)。去年有5家分析公司公布了评级。

What is the most recent analyst rating for Indaptus Therapeutics (INDP)?

Indaptus Treeutics(INDP)的最新分析师评级是多少?

The latest analyst rating for Indaptus Therapeutics (NASDAQ: INDP) was provided by HC Wainwright & Co., and Indaptus Therapeutics reiterated their buy rating.

对Indaptus治疗公司(纳斯达克代码:INDP)的最新分析师评级由HC Wainwright&Co.提供,Indaptus治疗公司重申了他们的买入评级。

When is the next analyst rating going to be posted or updated for Indaptus Therapeutics (INDP)?

Indaptus Treeutics(INDP)的下一次分析师评级将于何时发布或更新?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Indaptus Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Indaptus Therapeutics was filed on August 8, 2023 so you should expect the next rating to be made available sometime around August 8, 2024.

分析师在进行了广泛的研究后得出股票评级,其中包括查阅公共财务报表,与Indaptus Treeutics的高管和客户交谈,以及听取收益电话会议。大多数分析师每三个月就会这样做一次,所以你每年应该会得到每家公司每家公司的4个评级。Indaptus治疗公司的上一次评级是在2023年8月8日提交的,所以你应该预计下一次评级将在2024年8月8日左右提供。

Is the Analyst Rating Indaptus Therapeutics (INDP) correct?

分析师对Indaptus Treeutics(INDP)的评级正确吗?

While ratings are subjective and will change, the latest Indaptus Therapeutics (INDP) rating was a reiterated with a price target of $0.00 to $12.00. The current price Indaptus Therapeutics (INDP) is trading at is $1.85, which is within the analyst's predicted range.

虽然评级是主观的,并将发生变化,但最新的Indaptus治疗公司(INDP)评级被重申,目标价在0.00美元至12.00美元之间。Indaptus Treateutics(INDP)目前的交易价格为1.85美元,在分析师的预测范围内。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发